PARP1 and neoplasm: This strategy, which follows the principle of synthetic lethality, is applied in clinical trials and is effective in BRACA1/2-deficient tumours [75,76] and then extended to many other HR proteins deficiencies, such as deficiency in ATM and Rad51 [77]; for a list of clinical trials on PARP inhibitors, see Table 2.